# Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor

> **NCT02151357** · PHASE1 · TERMINATED · sponsor: **Standard Chem. & Pharm. Co., Ltd.** · enrollment: 17 (actual)

## Conditions studied

- Cancer

## Interventions

- **DRUG:** DCBCI0901

## Key facts

- **NCT ID:** NCT02151357
- **Lead sponsor:** Standard Chem. & Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-08-19
- **Primary completion:** 2016-06-24
- **Final completion:** 2016-10-31
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** catheter occlusion events during the study drug infusion
- **Last updated:** 2017-10-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02151357

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02151357, "Safety, Tolerability and Pharmacokinetics of DCBCI0901 in Patients With Advanced Solid Tumor". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02151357. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*